Chinese biotech CEOs target creation of up to ten global Big Pharma firms within a decade

Chinese drug developers have shifted from generic manufacturing to aiming for a seat at the global Big Pharma table, according to recent interviews.

The country now ranks second after the United States for clinical trial locations and leads in biotech licensing‑out deals, reflecting its growing innovation capacity.

CEOs say their strategies differ based on programs, cash flow, R&D focus and risk appetite, but many envision China producing five to ten global Big Pharma companies within the next five to ten years.

DualityBio, a Shanghai‑based firm, exemplifies this ambition, publicly stating its goal to become a global ADC powerhouse and recently signing a $1 billion antibody‑drug conjugate partnership with Roche’s Gene division.